https://lifesciences.mofo.com/ Keeping pace with the ever-changing life sciences industry, Morrison Foerster stays on top of the trends and political, legal, and economic drivers to support striking the balance between innovative discovery and purposeful business planning to assure our clients continued success. MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.Learn more about our Life Sciences practice.About Morrison FoersterMorrison Foerster is a leading global law firm that transforms complexity into advantage for its clients. Our clients include some of the largest financial institutions, banks, consulting and accounting firms, and Fortune 100, technology, and life sciences companies. Highlighting the firm’s commitment to client service, leadership in market-changing deals and impact litigation, and values-based culture, Morrison Foerster has been repeatedly recognized as one of the top 10 firms on The American Lawyer’s A-List. Year after year, the firm receives significant recognition from Chambers and The Legal 500 across their various guides, including Global, USA, Asia‑Pacific, Europe, UK, Latin America, and FinTech Legal. Our lawyers passionately care about delivering legal excellence while living our values. Morrison Foerster has a long-standing commitment to creating a culture that respects and celebrates differences, while providing an inclusive environment. The firm also has a long history of commitment to the community and society through providing pro bono legal services, including litigating for civil rights and civil liberties, improving public education and fostering the wellbeing of children, advocating for veterans, promoting international human rights, enforcing the right to asylum, and safeguarding the environment. Wed, 12 Aug 2026 16:49:55 GMT https://validator.w3.org/feed/docs/rss2.html Morrison Foerster RSS Generator https://media2.mofo.com/v3/assets/blt5775cc69c999c255/blt8906897ee1aa88fc/6283182abd980555189d32df/apple-touch-icon.png https://lifesciences.mofo.com/ All rights reserved Morrison Foerster LLP. All Rights Reserved. https://lifesciences.mofo.com//topics/uspto-reconsiders-obviousness-type-double-patenting-and-proposes-a-new-examination-framework https://lifesciences.mofo.com//topics/uspto-reconsiders-obviousness-type-double-patenting-and-proposes-a-new-examination-framework Mon, 10 Aug 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/cjeu-clarifies-when-a-healthcare-product-is-a-medical-device-under-the-mdr-beyond-the-brochure https://lifesciences.mofo.com//topics/cjeu-clarifies-when-a-healthcare-product-is-a-medical-device-under-the-mdr-beyond-the-brochure Tue, 21 Jul 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/cms-announces-pause-on-home-health-and-hospice-enrollments-amid-expanding-fraud-crackdown https://lifesciences.mofo.com//topics/cms-announces-pause-on-home-health-and-hospice-enrollments-amid-expanding-fraud-crackdown Thu, 14 May 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/new-coverage-pathway-for-medical-devices https://lifesciences.mofo.com//topics/new-coverage-pathway-for-medical-devices Wed, 29 Apr 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/fda-s-revised-biosimilar-q-as-three-things-sponsors-should-know https://lifesciences.mofo.com//topics/fda-s-revised-biosimilar-q-as-three-things-sponsors-should-know Tue, 17 Mar 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/usda-aphis-brs-promises-continued-efficiency https://lifesciences.mofo.com//topics/usda-aphis-brs-promises-continued-efficiency Wed, 11 Mar 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-plausible-mechanism-guidance https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-plausible-mechanism-guidance Thu, 26 Feb 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/recombinant-host-cells-are-patent-eligible-federal-circuit-revives-regenxbio-s-gene-delivery-patent https://lifesciences.mofo.com//topics/recombinant-host-cells-are-patent-eligible-federal-circuit-revives-regenxbio-s-gene-delivery-patent Mon, 23 Feb 2026 00:00:00 GMT https://lifesciences.mofo.com//topics/texas-sb-25-litigation-trade-associations-challenge-tx-warning-label-requirement https://lifesciences.mofo.com//topics/texas-sb-25-litigation-trade-associations-challenge-tx-warning-label-requirement Thu, 11 Dec 2025 00:00:00 GMT https://lifesciences.mofo.com//topics/blaze-marks-written-description-patent-drafting-lessons-duke-v-sandoz https://lifesciences.mofo.com//topics/blaze-marks-written-description-patent-drafting-lessons-duke-v-sandoz Wed, 10 Dec 2025 00:00:00 GMT https://lifesciences.mofo.com//topics/strategic-filing-of-ai-and-life-sciences-software https://lifesciences.mofo.com//topics/strategic-filing-of-ai-and-life-sciences-software Tue, 09 Dec 2025 00:00:00 GMT https://lifesciences.mofo.com//topics/europe-s-new-genomic-techniques-patent-ban-off-the-table https://lifesciences.mofo.com//topics/europe-s-new-genomic-techniques-patent-ban-off-the-table Mon, 08 Dec 2025 08:00:00 GMT https://lifesciences.mofo.com//topics/251024-biosecure-act-passes-senate https://lifesciences.mofo.com//topics/251024-biosecure-act-passes-senate Fri, 24 Oct 2025 00:00:00 GMT https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-newest-draft-guidance-on-cell-gene-therapies https://lifesciences.mofo.com//topics/three-things-to-know-about-fda-s-newest-draft-guidance-on-cell-gene-therapies Thu, 23 Oct 2025 00:00:00 GMT